Document Type
Journal Article
Publication Date
6-17-2017
Journal
Oncotarget
Volume
8
Issue
46
Inclusive Pages
81350-81360
DOI
10.18632/oncotarget.18531
Abstract
IL-18 polymorphisms influence the transcriptional activity of the IL-18 gene and associated with various diseases. However, their relationships with hepatitis B virus-related liver diseases had not reached a consensus. So we conducted this case-control study with a view to clarifying the association. We included four groups: healthy controls, chronic hepatitis B virus (CHB) carriers, liver cirrhosis (LC) and hepatocellular carcinoma (HCC) groups with each group of 250 persons. Odd ratios (ORs) and 95% confidence intervals (95%CIs) with or without adjustment were calculated. Haplotype analysis was also performed. The results showed people carrying rs187238 CG genotype had a lower risk of LC (CG vs. CC: OR = 0.59, 95%CI = 0.38–0.91, P = 0.02), while GG genotype carriers had a higher risk of HCC (GG vs. CC+CG: OR = 4.73, 95%CI = 1.01–22.1, P = 0.03) than those with CC and CG genotypes in healthy group. Rs187238 GG genotype increased the risk from CHB to LC status (GG vs. CC: OR = 4.81, 95%CI = 1.03–22.6; GG vs. CC+CG: OR = 4.73, 95%CI = 1.01–22.1), meanwhile the trend also existed by controlling confounding factors (GG vs. CC: OR = 6.25, 95%CI = 1.09–35.8; GG vs. CC+CG: OR = 5.91, 95%CI = 1.04–33.7). Haplotype Crs187238Trs1946518 moderately decreased the risk of CHB carriers developing into HCC (OR = 0.69, 95%CI = 0.50–0.96, P = 0.03) after adjustment. In conclusion, IL-18 rs187238 GG genotype may increase the risk of HCC in healthy population and the risk of LC in CHB carriers.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
APA Citation
Dai, Z., Liu, X., Wang, M., Guo, Y., Zhu, W., Li, X., Lin, S., Tian, T., Liu, K., Zheng, Y., Xu, P., Jin, T., & Li, X. (2017). IL-18 Polymorphisms Contribute To Hepatitis B Virus-Related Cirrhosis and Hepatocellular Carcinoma Susceptibility in Chinese Population: A Case-Control Study.. Oncotarget, 8 (46). http://dx.doi.org/10.18632/oncotarget.18531
Peer Reviewed
1
Open Access
1
Comments
Reproduced with permission of Impact Journals LLC. Oncotarget